Cited 10 times in
Synthesized pyridine compound derivatives decreased TNF alpha and adhesion molecules and ameliorated HSV-induced inflammation in a mouse model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 방동식 | - |
dc.date.accessioned | 2014-12-20T16:35:29Z | - |
dc.date.available | 2014-12-20T16:35:29Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0014-2999 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/93005 | - |
dc.description.abstract | Synthesized pyridine compound derivatives (SK94, SK126) from a natural lead source were administered to mice to test for possible anti-TNF alpha and anti-inflammatory activities. Lipopolysaccharide (LPS)-induced TNF alpha production was analyzed in the endothelial cells, Raw 264.7 cells, and serum of normal mice after treatment with SK compounds. These compounds were also orally administered to a herpes simplex virus (HSV)-induced Behcet's disease mouse model to investigate their anti-inflammatory therapeutic effect. TNF alpha production was inhibited in a dose-dependent manner in the SK94 treated cells. E-selectin, VCAM-1, and ICAM-1 mRNA levels were also down-regulated. Treatment with 30mg/kg SK94 inhibited 55% of the TNF alpha production in LPS challenged Balb/c mice (n=8). SK94 and SK126 were administered to the Behcet's disease-like mice for five consecutive days and SK94 improved in five out of six mice (83%), while it only improved in one out of nine mice (11%) in the pH 1.2 saline (artificial gastric juice) group (P<0.005), four out of ten mice (40%) in the thalidomide group (P<0.05), and six out of seven (86%) in the SK126 group (P<0.005). Soluble ICAM-1 was inhibited by 23.8% in the sera of SK94 treated mice and by 34.6% in SK126 treated mice when compared to artificial gastric juice. Based on these findings, SK compounds could be candidates for clinical trials. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 167~172 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Behcet Syndrome/drug therapy | - |
dc.subject.MESH | Behcet Syndrome/genetics | - |
dc.subject.MESH | Behcet Syndrome/metabolism* | - |
dc.subject.MESH | Behcet Syndrome/virology* | - |
dc.subject.MESH | Cell Adhesion Molecules/genetics | - |
dc.subject.MESH | Cell Adhesion Molecules/metabolism* | - |
dc.subject.MESH | Cell Line | - |
dc.subject.MESH | Disease Models, Animal | - |
dc.subject.MESH | Down-Regulation/drug effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Molecular Weight | - |
dc.subject.MESH | Naphthyridines/administration & dosage | - |
dc.subject.MESH | Naphthyridines/chemical synthesis | - |
dc.subject.MESH | Naphthyridines/chemistry | - |
dc.subject.MESH | Naphthyridines/pharmacology | - |
dc.subject.MESH | Pyridines/administration & dosage | - |
dc.subject.MESH | Pyridines/chemical synthesis | - |
dc.subject.MESH | Pyridines/chemistry* | - |
dc.subject.MESH | Pyridines/pharmacology* | - |
dc.subject.MESH | RNA, Messenger/genetics | - |
dc.subject.MESH | RNA, Messenger/metabolism | - |
dc.subject.MESH | Simplexvirus/physiology* | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/antagonists & inhibitors | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/biosynthesis | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/metabolism* | - |
dc.title | Synthesized pyridine compound derivatives decreased TNF alpha and adhesion molecules and ameliorated HSV-induced inflammation in a mouse model | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Dermatology (피부과학) | - |
dc.contributor.googleauthor | Bunsoon Choi | - |
dc.contributor.googleauthor | Joohyon Kim | - |
dc.contributor.googleauthor | Eun-So Lee | - |
dc.contributor.googleauthor | Dongsik Bang | - |
dc.contributor.googleauthor | Seonghyang Sohn | - |
dc.identifier.doi | 10.1016/j.ejphar.2011.01.062 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01784 | - |
dc.relation.journalcode | J00842 | - |
dc.identifier.eissn | 1879-0712 | - |
dc.identifier.pmid | 21315710 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0014299911001208 | - |
dc.subject.keyword | Pyridine compound derivative | - |
dc.subject.keyword | Behcet's disease | - |
dc.subject.keyword | Herpes simplex virus | - |
dc.subject.keyword | TNF alpha | - |
dc.subject.keyword | Oral administration | - |
dc.subject.keyword | Anti-inflammation | - |
dc.subject.keyword | Mouse model | - |
dc.contributor.alternativeName | Bang, Dong Sik | - |
dc.contributor.affiliatedAuthor | Bang, Dong Sik | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 657 | - |
dc.citation.number | 1-3 | - |
dc.citation.startPage | 167 | - |
dc.citation.endPage | 172 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF PHARMACOLOGY, Vol.657(1-3) : 167-172, 2011 | - |
dc.identifier.rimsid | 27965 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.